AVITA Medical, headquartered in Valencia, California, secured a 10-year agreement valued at up to $25.5 million with the Biomedical Advanced Research and Development Authority (BARDA) on April 8, 2026. BARDA operates as part of the Administration for Strategic Preparedness and Response inside the U.S. Department of Health and Human Services. The contract, awarded under Project BioShield, stocks RECELL skin units for rapid deployment in national emergency burn mass casualty incidents across the United States.
The deal gives BARDA immediate access to 3,000 units of RECELL products at any time during the 10-year term. AVITA Medical must maintain an on-hand inventory ready for deployment upon notice. The company will also handle:
- Logistics, quality assurance, and full deployment readiness services.
- Surge procurement options if BARDA needs additional units during an actual incident.
- Fixed annual access-maintenance fees and readiness support payments (approximately $3.97 million) spread over the decade.
RECELL is an autologous cell harvesting device approved by the FDA for treatment of acute thermal burn wounds and full-thickness skin defects. Surgeons use it at the point of care. They take a small sample of the patient’s own skin, often the size of a postage stamp. The device processes this sample in about 30 minutes to create a suspension of Spray-On Skin Cells. These cells include:
- Keratinocytes
- Fibroblasts
- Melanocytes
The suspension is sprayed directly onto prepared wound beds. For partial-thickness burns in adults 18 and older, RECELL works alone. For full-thickness burns in adults and children, it combines with widely meshed autografts. It also applies to full-thickness skin defects from trauma, surgical excision, or other causes in patients 15 and older.
Traditional burn treatment relies on split-thickness skin grafts. These require large donor sites from the patient’s body. Harvesting those sites creates additional wounds that cause pain, scarring, and longer recovery. RECELL reduces donor skin needs by up to 80 times the area of the original sample in some applications. Clinical trials and real-world data from more than 6,300 patients in U.S. burn centers between 2019 and 2024 show:
- Faster wound closure.
- Reduced hospital length of stay by an average of 2.1 days for certain deep partial-thickness burns.
- Lower overall treatment costs, with one analysis linking use to savings of approximately $22,268 per patient.
BARDA’s involvement with RECELL dates back years. The agency previously funded clinical trials that supported the original FDA approval in September 2018 and later expansions. Those trials included randomized controlled studies that proved RECELL required substantially less donor skin than standard grafting while achieving equivalent or better healing. The new 10-year agreement builds directly on that foundation. It shifts focus from development to sustained national stockpiling and readiness. AVITA Medical already operates manufacturing under strict GMP and ISO 13485 standards. The company acquired its primary production facility in Ventura, California, in 2018 partly to meet earlier BARDA procurement requirements.
Burn mass casualty incidents pose unique challenges. Explosions, industrial accidents, wildfires, or terrorist events can overwhelm local hospitals within hours. Standard skin grafting demands operating room time, large donor harvests, and extended intensive care. RECELL changes the equation. Its point-of-care preparation allows treatment without massive donor sites. This preserves healthy skin on severely burned patients who may have limited unburned areas left. Faster healing reduces infection risk, ventilator days, and overall hospital burden. In a true mass casualty scenario, these differences determine how many patients survive and recover with functional skin.
The contract requires AVITA Medical to keep RECELL units stored and ready for immediate shipment anywhere in the country. BARDA can call them up without delay. The agreement also covers training and support so burn centers can integrate the system quickly during a surge. This level of preparedness addresses gaps exposed in past disasters where skin replacement resources ran short. Federal stockpiling of advanced regenerative tools like RECELL directly counters those vulnerabilities.
AVITA Medical developed RECELL over more than a decade. Early work involved collaboration with U.S. Department of Defense programs and BARDA funding for pediatric burn studies. FDA granted expedited access pathway status in 2015 because the technology addressed a life-threatening condition. Full approval followed in 2018 for adult thermal burns. Subsequent supplements expanded indications to full-thickness defects and added the next-generation RECELL GO system in 2024. RECELL GO offers improved workflow while delivering the same Spray-On Skin Cells. A smaller RECELL GO mini version handles limited wounds. All versions remain autologous, eliminating rejection risks associated with donor tissue or synthetic products.
Real-world evidence continues to accumulate. Presentations at major burn association meetings document reduced donor site morbidity, better pigmentation, and improved cosmetic outcomes. Hospitals report lower inpatient resource demands. These outcomes matter in routine care and become critical in emergencies when systems face hundreds of patients at once.
The $25.5 million agreement represents a targeted investment in domestic preparedness. It does not rely on foreign suppliers for this critical medical countermeasure. Production stays under U.S. control. Inventory remains on American soil. Deployment logistics align with national emergency response frameworks. This structure avoids delays that could cost lives when every hour counts in burn care.
AVITA Medical will recognize steady revenue from the maintenance and readiness fees regardless of whether BARDA exercises procurement options. The company gains a long-term federal partner committed to burn response capability. For patients, the contract means that in the next mass casualty event, frontline burn teams will have access to a proven regenerative tool already positioned for rapid use.
No public details have emerged about specific pricing per unit or exact storage locations beyond the requirement for immediate availability. The agreement focuses on capability rather than large upfront purchases. BARDA retains flexibility to scale response based on the scale of any future incident.
This contract places RECELL into the national strategic reserve for burn emergencies. It equips the country with technology that treats more patients with less donor skin, shorter hospital stays, and better functional recovery. The move strengthens defenses against disasters that have historically strained medical systems beyond capacity.
The federal government has now locked in ready access to 3,000 RECELL units for the next decade to protect Americans in the event of a major burn mass casualty incident.
